



Grŵp Strategaeth Meddyginiaethau Cymru Gyfan All Wales Medicines Strategy Group

**Meeting to commence at 9.30 am
on Tuesday 18th October 2022
Via Zoom**

AGENDA

Enclosure

1. **Welcome and introduction**
 2. **Apologies**
 3. **Declarations of interest**
 4. **Minutes of the previous meeting** 1/AWMSG/1022
 5. **Chairman's report**
 6. **Paediatric Licence Extensions: confirmation of approval of draft recommendations**

Ambrisentan (Volibris®) for the treatment of PAH in adolescents and children (aged 8 to less than 18 years) of WHO Functional Class (FC) II to III including use in combination treatment. Efficacy has been shown in IPAH, familial, corrected congenital and in PAH associated with connective tissue disease 2/AWMSG/1022 Appendices

Migalastat (Galafold®) for long-term treatment of adolescents aged 12-15 years with a confirmed diagnosis of Fabry disease (α -galactosidase A deficiency) and who have an amenable mutation 3/AWMSG/1022 Appendices

Bedaquiline (Sirturo®) for use as part of an appropriate combination regimen for pulmonary multidrug-resistant tuberculosis (MDR-TB) in paediatric patients (5 years to less than 12 years of age and weighing at least 15 kg) when an effective treatment regimen cannot otherwise be composed for reasons of resistance or tolerability 4/AWMSG/1022 Appendices
 7. **Appraisal 1 – Full re-submission** 5/AWMSG/1022 Appendices
Ferric maltol (Feraccru®) for the treatment of iron deficiency in adults
 8. **Guide to collaborative working between NHS Wales and the pharmaceutical industry- document review/update for information only** 6/AWMSG/1022
 9. **Feedback from AWPAG:**
Draft notes from June meeting 7/AWMSG/1022
Verbal feedback from September meeting
 10. **AWMSG 20th Anniversary Conference programme – for information** 8/AWMSG/1022
 11. **Any other business**
- Date and time of next meeting: Tuesday 6th December at 9:30am**